Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HealthPrize Technologies LLC

Winning at medication adherence

This article was originally published in Start Up

Executive Summary

HealthPrize Technologies LLC, a company developing Internet and mobile-based gaming and loyalty rewards applications, hopes to teach the industry how to motivate reluctant patients to take their medicine. By making behavioral psychology part of the prescription, the start-up thinks that pharmaceutical companies, payors and providers will reward it for boosting adherence rates.

You may also be interested in...



Improved Adherence To Diabetes Drugs Can Lower Hospitalizations 13%, Study Finds

Researchers at Harvard and Express Scripts estimate that improved adherence to diabetes drugs could save nearly $5 billion annually across the U.S. health care system.

Making The Business Of Drug Adherence An Easier Pill To Swallow

Medication adherence is a big problem, and recent studies are bringing the actual costs and causes into sharper focus. At the same time, health care reforms such as electronic health records and prescriptions, as well as new incentives from the US government, have encouraged investors to tackle solutions to the problem. Questions remain about the impact of these reforms, but the companies profiled in this issue, HealthPrize Technologies, PillJogger, RxAnte and SentiCare, see an evolving climate in which their medication adherence technology solutions can turn into profitable businesses.

With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology

BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.

Topics

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel